Gyre Therapeutics, Inc. (GYRE) is a commercial-stage biopharmaceutical company that develops and sells small-molecule therapies for organ fibrosis and inflammatory disease, operating a revenue-generating Chinese subsidiary, Gyre Pharmaceuticals, alongside a U.S. pipeline led by hydronidone (F351) for liver fibrosis. In the opening hour of trading on Nov. 19, the stock traded at $4.65, up $0.31, or 7.14%, from the previous session's close of $4.34. The direction was firmly positive, with the advance building on a pre-market gap higher. No verified news catalyst was found for the move.
No verified news or fundamental catalyst found for the Nov. 19 advance. No press release, Form 8-K, financing, analyst action or regulatory update was published before the move began. The gain therefore appears technical and flow-driven rather than event-driven.
The price action is consistent with a rebound inside an established downtrend, amplified by thin liquidity. Shares closed at $4.01 on Nov. 5, close to the 52-week low of $3.97, then jumped 18.70% on Nov. 6 in the session after quarterly results, before sliding back to $4.34 by Nov. 18. That pattern — sharp rallies followed by renewed selling — has repeated across the past three months, during which the stock has fallen roughly 38%. A modest pre-market bid on very light volume was enough to set a higher opening print, a dynamic typical of micro- and small-cap biotech names with limited float.
Secondary support likely comes from positioning around the pending Chinese regulatory decision on F351, which management has guided to year-end 2026 or the first quarter of 2027. That catalyst remains unresolved and is not a same-day event, but it sustains speculative interest in the name.
Turnover was light in the opening minutes, with only a few thousand shares changing hands shortly after the bell and negligible pre-market volume. Against a 20-day average of roughly 243,000 shares, that suggests the percentage move overstates the depth of real demand. The stock's beta of roughly 4.9 confirms it is prone to outsized reactions to relatively small order flow.
Nothing in the broader tape — no macro data release, no sector-wide regulatory headline — was identified as a driver, so the move looks company-specific rather than part of an industry or index-wide rally.
Technically, the shares remain deeply depressed. At $4.65, the stock trades about 24% below its 50-day moving average near $6.15 and roughly 31% below its 200-day average of about $6.76. The $4.00 area has acted as support following the Oct. 30 selloff, while the $4.70–$4.80 zone, where the stock stalled on Nov. 6 and Nov. 18 intraday, is the nearest resistance. Short interest of roughly 2.2 million shares adds a squeeze component to any sharp rally.
The score runs from 0 to 100, where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news combined with an extreme, rare price move. This event scores 13 out of 100.
No verified news was found, and the only fundamental backdrop is a third-quarter report two weeks old that beat expectations and affirmed guidance — material to the company's story but unrelated to today's session. The advance of 7.14% was roughly 2.1 times the stock's average absolute daily move of about 3.4% over the past three months, and eight of the previous 60 sessions produced equal or larger swings. Weak news and an unremarkable move relative to this stock's own history combine into a low score.
Attention remains fixed on China's National Medical Products Administration and its review of the hydronidone NDA for chronic hepatitis B-associated liver fibrosis, with a decision guided to year-end 2026 or early 2027. Fourth-quarter and full-year 2026 results are due around March, and investors will watch whether revenue lands inside the affirmed $100.5 million to $111.0 million range as centralized procurement pressure weighs on the Contiva and Etorel product lines.
Analyst coverage is thin, with a small group of firms carrying constructive ratings, so individual notes can move the stock disproportionately. Key risks include regulatory delay or rejection in China, further pricing pressure from national procurement, continued cash burn tied to the Cullgen protein-degradation pipeline, and the possibility that the current rebound fades, as prior ones have.
Tickeron's Trending AI Robots page offers a curated view of automated trading strategies that are outperforming in current market conditions. Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers are featured in this section. Bots differ by strategy, timeframe, performance metrics and the symbols they trade, letting users compare approaches side by side. Visitors can review the current lineup to see which strategies are working — and explore how they might fit a broader trading plan.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
GYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 32 cases where GYRE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GYRE's RSI Indicator exited the oversold zone, 35 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where GYRE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on GYRE as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for GYRE just turned positive on November 17, 2026. Looking at past instances where GYRE's MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.
Following a +5.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GYRE advanced for three days, in 216 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
GYRE moved below its 50-day moving average on October 29, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GYRE crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
The Aroon Indicator for GYRE entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.676) is normal, around the industry mean (3.596). P/E Ratio (-23.800) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (6.536) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. GYRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology